Foamix and Galderma to develop medicated foam for certain skin diseases
Israel-based Foamix, a global leader in the development of dermatological foam medications, and French speciality pharmaceutical company Galderma have signed an agreement to develop jointly an innovative medicated foam. This new therapy contains a novel drug for the treatment of certain skin diseases.
Israel-based Foamix, a global leader in the development of dermatological foam medications, and French speciality pharmaceutical company Galderma have signed an agreement to develop jointly an innovative medicated foam. This new therapy contains a novel drug for the treatment of certain skin diseases.
Under the agreement, Foamix will develop the foam formulation of the product and Galderma will subsequently conduct all other clinical and non-clinical activities. Foamix will receive staged payments on successful completion of the technical milestones of the project.
Headquartered in Ness Ziona, Israel, Foamix is a leading developer of topical foams for dermatology and gynaecology; the foams provide controlled delivery of a variety of active ingredients. The company is currently collaborating with 10 pharmaceutical companies on 11 projects in the development of proprietary dermatological and gynaecological foam drugs, and has its own in-house pipeline of dermatological and gynecological drugs in foam presentation.